Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifapentine plus moxifloxacin for onchocerciasis
ISRCTN43697583Phase 2Completed
- Sponsor
- Kumasi Centre for Collaborative Research in Tropical Medicine
- Start
- Oct 2018
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of rifapentine, moxifloxacin, doxycycline and ivermectin in onchocerciasis (4 arms), sponsored by Kumasi Centre for Collaborative Research in Tropical Medicine. Primary endpoint: Absence of Wolbachia endobacteria in female adult worms. Started Oct 2018; status: completed.
02
Drugs
rifapentinemoxifloxacindoxycyclineivermectin
03
Conditions
onchocerciasis
Beyond the preview
Go deeper on ISRCTN43697583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN43697583.